Papel de la microbiota intestinal en la infección por SARS-CoV-2 y los beneficios de los probióticos en el manejo de la enfermedad
DOI:
https://doi.org/10.33448/rsd-v11i7.30040Palabras clave:
COVID-19; Sistema renina-angiotensina; Inflamación; Vacunas.Resumen
Meta: El objetivo de este estudio fue presentar información sobre los efectos de los probióticos en el estado inflamatorio y el equilíbrio Sistema Renina-Angiotensina (RAS), el potencial terapéutico en el manejo de COVID-19. Metodología: Se trata de una revisión narrativa y las bases de datos utilizadas fueron Google Scholar y Medline/Pubmed. Resultados: Coprobacillus, Clostridium ramosum, Morganella morganii y Streptococcus infantil de la microbiota intestinal mostraron una correlación positiva con la gravedad de la enfermedad, mientras que una correlación negativa se asoció con Faecalibacterium prausnitzii en la infección por SARS-CoV-2. Debido a la capacidad de mantener la integridad y reparar el daño intestinal, los probióticos emergen como una alternativa terapéutica para el tratamiento de enfermedades relacionadas con el metabolismo y condiciones inflamatorias inducidas por infecciones intestinales. Los probióticos de los géneros Bifidobacterium y Lactobacillus muestran beneficios en enfermedades respiratorias además de aumentar la inmunogenicidad de las vacunas. Conclusión: El presente estudio demuestra el potencial terapéutico complementario de los probióticos en el tratamiento de infecciones respiratorias, incluida la COVID-19. Además, considerando la diversidad de cepas probióticas, las evaluaciones ya realizadas y los datos disponibles en la literatura, el presente estudio también apunta a la necesidad de estudios complementarios que busquen comprender los mecanismos relacionados con los efectos de los probióticos en la COVID-19.
Citas
Abdel-Hamed, E. F., Ibrahim, M. N., Mostafa, N. E., Moawad, H. S. F., Elgammal, N. E., Darwiesh, E. M., El-rafey, D. S., ElBadawy, N. E., Al-Khoufi, E. A., & Hindawi, S. I. (2021). Role of interferon gamma in SARS-CoV-2-positive patients with parasitic infections. Gut Pathogens, 13(1), 1–7. https://doi.org/10.1186/s13099-021-00427-3
Adak, A., & Khan, M. (2019). An insight into gut microbiota and its functionalities. Cellular and Molecular Life Science, 76, 473–493.
Akour, A. (2020). Probiotics and COVID‐19: is there any link? Letters in Applied Microbiology, 71(3), 229–234. https://doi.org/10.1111/lam.13334
Aktas, B., & Aslim, B. (2020). Gut-lung axis and dysbiosis in COVID-19. Turkish Journal of Biology, 44(3), 265–272. https://doi.org/10.3906/biy-2005-102
Almada, C. N. De, Almada, C. N. De, Martinez, R. C. R., & Sant’Ana, A. de S. (2015). Characterization of the intestinal microbiota and its interaction with probiotics and health impacts. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-015-6582-5
Antunes, A. E. C., Vinderola, G., Santos, D. X., & Sivieri, K. (2020). Potential contribution of beneficial microbes to face the COVID-19 pandemic. Food Reasearch International, 136.
Azad, M. A. K., Sarker, M., & Wan, D. (2018). Immunomodulatory Effects of Probiotics on Cytokine Profiles. BioMed Research International, 2018. https://doi.org/10.1155/2018/8063647
Barssotti, L., Abreu, I. C. M. E., Brandão, A. B. P., Albuquerque, R. C. M. F., Ferreira, F. G., Salgado, M. A. C., Dias, D. D. S., De Angelis, K., Yokota, R., Casarini, D. E., Souza, L. B., Taddei, C. R., & Cunha, T. S. (2021). Saccharomyces boulardii modulates oxidative stress and renin angiotensin system attenuating diabetes-induced liver injury in mice. In Scientific Reports (Vol. 11, Issue 1). https://doi.org/10.1038/s41598-021-88497-w
Battaglini, D., Robba, C., Fedele, A., Trancǎ, S., Sukkar, S. G., Di Pilato, V., Bassetti, M., Giacobbe, D. R., Vena, A., Patroniti, N., Ball, L., Brunetti, I., Torres Martí, A., Rocco, P. R. M., & Pelosi, P. (2021). The Role of Dysbiosis in Critically Ill Patients With COVID-19 and Acute Respiratory Distress Syndrome. Frontiers in Medicine, 8(June), 1–19. https://doi.org/10.3389/fmed.2021.671714
Baud, D., Dimopoulou Agri, V., Gibson, G. R., Reid, G., & Giannoni, E. (2020). Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic. Frontiers in Public Health, 8(May), 1–5. https://doi.org/10.3389/fpubh.2020.00186
Belkaid, Y. and T. H. (2015). Role of the Microbiota in Immunity and inflammation. Cell, 157(1), 121–141. https://doi.org/10.1016/j.cell.2014.03.011.Role
Benigni, A., Corna, D., Zoja, C., Sonzogni, A., Latini, R., Salio, M., Conti, S., Rottoli, D., Longaretti, L., Cassis, P., Morigi, M., Coffman, T. M., & Remuzzi, G. (2009). Disruption of the Ang II type 1 receptor promotes longevity in mice. The Journal of Clinical Investigation, 119(3), 524–530. https://doi.org/10.1172/JCI36703
Bottari, B., Castellone, V., & Neviani, E. (2021). Probiotics and Covid-19. International Journal of Food Sciences and Nutrition, 72(3), 293–299. https://doi.org/10.1080/09637486.2020.1807475
Britton, G. J., Chen-Liaw, A., Cossarini, F., Livanos, A. E., Spindler, M. P., Plitt, T., Eggers, J., Mogno, I., Gonzalez-Reiche, A. S., Siu, S., Tankelevich, M., Grinspan, L. T., Dixon, R. E., Jha, D., van de Guchte, A., Khan, Z., Martinez-Delgado, G., Amanat, F., Hoagland, D. A., … Faith, J. J. (2021). Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. Scientific Reports, 11(1), 13308. https://doi.org/10.1038/s41598-021-92740-9
Buts, J.-P. (1999). Mechanisms of Action of Biotherapeutic Agents. Biotherapeutic Agents and Infectious Diseases, 27–46. https://doi.org/10.1007/978-1-59259-711-6_2
Campione, E., Cosio, T., Rosa, L., Lanna, C., Girolamo, S. Di, Gaziano, R., Valenti, P., & Bianchi, L. (2020). Lactoferrin as protective natural barrier of respiratory and intestinal mucosa against coronavirus infection and inflammation. International Journal of Molecular Sciences, 21(14), 1–14. https://doi.org/10.3390/ijms21144903
Carter, C. S., Morgan, D., Verma, A., Lobaton, G., Aquino, V., Sumners, E., Raizada, M., Li, Q., & Buford, T. W. (2020). Therapeutic delivery of ang(1-7) via genetically modified probiotic: A dosing study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 75(7), 1299–1303. https://doi.org/10.1093/gerona/glz222
Ceccarelli, G., Borrazzo, C., Pinacchio, C., Santinelli, L., Innocenti, G. Pietro, Cavallari, E. N., Celani, L., Marazzato, M., Alessandri, F., Ruberto, F., Pugliese, F., Venditti, M., Mastroianni, C. M., & d’Ettorre, G. (2021). Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. Frontiers in Nutrition, 7(January), 1–8. https://doi.org/10.3389/fnut.2020.613928
Cenit, M. C., Sanz, Y., & Codoñer-Franch, P. (2017). Influence of gut microbiota on neuropsychiatric disorders. World Journal of Gastroenterology, 23(30), 5486–5498. https://doi.org/10.3748/wjg.v23.i30.5486
Chattopadhyay, I., & Shankar, E. M. (2021). SARS-CoV-2-Indigenous Microbiota Nexus: Does Gut Microbiota Contribute to Inflammation and Disease Severity in COVID-19? Frontiers in Cellular and Infection Microbiology, 11(March), 1–8. https://doi.org/10.3389/fcimb.2021.590874
Chen, J., Vitetta, L., Henson, J. D., & Hall, S. (2021). The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. Journal of Functional Foods, 87(January), 104850. https://doi.org/10.1016/j.jff.2021.104850
Chong, H. X., Yusoff, N. A. A., Hor, Y. Y., Lew, L. C., Jaafar, M. H., Choi, S. B., Yusoff, M. S. B., Wahid, N., Abdullah, M. F. I. L., Zakaria, N., Ong, K. L., Park, Y. H., & Liong, M. T. (2019). Lactobacillus plantarum DR7 improved upper respiratory tract infections via enhancing immune and inflammatory parameters: A randomized, double-blind, placebo-controlled study. Journal of Dairy Science, 102(6), 4783–4797. https://doi.org/10.3168/jds.2018-16103
de Jong, S. E., Olin, A., & Pulendran, B. (2020). The Impact of the Microbiome on Immunity to Vaccination in Humans. Cell Host and Microbe, 28(2), 169–179. https://doi.org/10.1016/j.chom.2020.06.014
Delgado-Gonzalez, P., Gonzalez-Villarreal, C. A., Roacho-Perez, J. A., Quiroz-Reyes, A. G., Islas, J. F., Delgado-Gallegos, J. L., Arellanos-Soto, D., Galan-Huerta, K. A., & Garza-Treviño, E. N. (2021). Inflammatory effect on the gastrointestinal system associated with COVID-19. World Journal of Gastroenterology, 27(26), 4160–4171. https://doi.org/10.3748/wjg.v27.i26.4160
Dhar, D., & Mohanty, A. (2020). Gut microbiota and Covid-19- possible link and implications. Virus Research, 285, 198018. https://doi.org/10.1016/j.virusres.2020.198018
Gasmi, A., Mujawdiya, P. K., Pivina, L., Doşa, A., Semenova, Y., Benahmed, A. G., & Bjørklund, G. (2020). Relationship between Gut Microbiota, Gut Hyperpermeability and Obesity. Current Medicinal Chemistry, 28(4), 827–839. https://doi.org/10.2174/0929867327666200721160313
Gutiérrez-Castrellón, P., Gandara-Martí, T., Abreu Y Abreu, A. T., Nieto-Rufino, C. D., López-Orduña, E., Jiménez-Escobar, I., Jiménez-Gutiérrez, C., López-Velazquez, G., & Espadaler-Mazo, J. (2022). Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes, 14(1). https://doi.org/10.1080/19490976.2021.2018899
Harrison, O. J., & Powrie, F. M. (2013). Regulatory T cells and immune tolerance in the intestine. Cold Spring Harbor Perspectives in Biology, 5(7), 1–17. https://doi.org/10.1101/cshperspect.a018341
He, L. H., Ren, L. F., Li, J. F., Wu, Y. N., Li, X., & Zhang, L. (2020). Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection. Frontiers in Microbiology, 11(June). https://doi.org/10.3389/fmicb.2020.01388
Hunt, R. H., East, J. E., Lanas, A., Malfertheiner, P., Satsangi, J., Scarpignato, C., & Webb, G. J. (2021). COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. Digestive Diseases, 39(2), 119–139. https://doi.org/10.1159/000512152
Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2021). Mechanisms of SARS-CoV-2 entry into cells. Nature Reviews Molecular Cell Biology, 0123456789. https://doi.org/10.1038/s41580-021-00418-x
Jaworska, K., Koper, M., & Ufnal, M. (2021). Gut microbiota and renin-angiotensin system: A complex interplay at local and systemic levels. American Journal of Physiology - Gastrointestinal and Liver Physiology, 321(4), G355–G366. https://doi.org/10.1152/ajpgi.00099.2021
Kim, H. S. (2021). Do an altered gut microbiota and an associated leaky gut affect COVID-19 severity? MBio, 12(1), 1–9. https://doi.org/10.1128/mBio.03022-20
Kim, M., & Kim, C. H. (2017). Regulation of humoral immunity by gut microbial products. 8(4), 392–399.
Kim, S., Goel, R., Kumar, A., Qi, Y., Lobaton, G., Hosaka, K., Mohammed, M., Handberg, E. M., Richards, E. M., Pepine, C. J., & Raizada, M. K. (2018). Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. 132(6), 701–718. https://doi.org/10.1042/CS20180087.Imbalance
Kopel, J., Perisetti, A., Gajendran, M., Boregowda, U., & Goyal, H. (2020). Clinical Insights into the Gastrointestinal Manifestations of COVID-19. Digestive Diseases and Sciences, 65(7), 1932–1939. https://doi.org/10.1007/s10620-020-06362-8
Kurian, S. J., Unnikrishnan, M. K., Miraj, S. S., Bagchi, D., Banerjee, M., Reddy, B. S., Rodrigues, G. S., Manu, M. K., Saravu, K., Mukhopadhyay, C., & Rao, M. (2021). Probiotics in Prevention and Treatment of COVID-19: Current Perspective and Future Prospects. Archives of Medical Research, 52(6), 582–594. https://doi.org/10.1016/j.arcmed.2021.03.002
Leal-Martínez, F., Abarca-Bernal, L., García-Pérez, A., González-Tolosa, D., Cruz-Cázares, G., Montell-García, M., & Ibarra, A. (2022). Effect of a Nutritional Support System to Increase Survival and Reduce Mortality in Patients with COVID-19 in Stage III and Comorbidities: A Blinded Randomized Controlled Clinical Trial. International Journal of Environmental Research and Public Health, 19(3). https://doi.org/10.3390/ijerph19031172
Lei, W., Shih, P., & Liu, S. (2017). Effect of Probiotics and Prebiotics on Immune Response to Influenza Vaccination in Adults : A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 9. https://doi.org/10.3390/nu9111175
Litvak, Y., Byndloss, M. X., & Bäumler, A. J. (2018). Colonocyte metabolism shapes the gut microbiota. In Science (Vol. 362, Issue 6418). https://doi.org/10.1126/science.aat9076
Lynn, D. J., Benson, S. C., Lynn, M. A., & Pulendran, B. (2021). Modulation of immune responses to vaccination by the microbiota: implications and potential mechanisms. Nature Reviews Immunology, 0123456789. https://doi.org/10.1038/s41577-021-00554-7
Lynn, D. J., & Pulendran, B. (2017). The potential of the microbiota to influence vaccine responses. Journal of Leukocyte Biology, 103(2), 225–231. https://doi.org/10.1189/jlb.5MR0617-216R
Mirzaei, R., Attar, A., Papizadeh, S., Salimi, A., Seyed, J., & Hosseini, R. (2021). The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 ( COVID ‑ 19 ). Archives of Virology, 166(7), 1819–1840. https://doi.org/10.1007/s00705-021-05036-8
Mitsuyama, K., Tsuruta, K., Takedatsu, H., Yoshioka, S., Morita, M., Niwa, M., & Matsumoto, S. (2020). Clinical Features and Pathogenic Mechanisms of Gastrointestinal Injury in COVID-19. Journal of Clinical Medicine, 9(11), 3630. https://doi.org/10.3390/jcm9113630
Mrityunjaya, M., Pavithra, V., Neelam, R., Janhavi, P., Halami, P. M., & Ravindra, P. V. (2020). Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19. In Frontiers in Immunology (Vol. 11). https://doi.org/10.3389/fimmu.2020.570122
Mullish, B. H., Marchesi, J. R., McDonald, J. A. K., Pass, D. A., Masetti, G., Michael, D. R., Plummer, S., Jack, A. A., Davies, T. S., Hughes, T. R., & Wang, D. (2021). Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics? Gut Microbes, 13(1), 1–9. https://doi.org/10.1080/19490976.2021.1900997
Olaimat, A. N., Aolymat, I., Al-holy, M., Ayyash, M., Ghoush, M. A., Osaili, T., Apostolopoulos, V., Liu, S., & Shah, N. P. (2020). The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. Npj Science of Food. https://doi.org/10.1038/s41538-020-00078-9
Oliveira, L. C. G., Cruz, N. A. N., Ricelli, B., Tedesco-Silva Jr, H., Medina-Pestana, J. O., & Casarini, D. E. (2021). Interactions amongst inflammation, renin-angiotensin-aldosterone and kallikrein-kinin systems: suggestive approaches for COVID-19 therapy. Journal of Venomous Animals and Toxins Including Tropical Diseases, 27(December 2021), 1–12. https://doi.org/10.1590/1678-9199-jvatitd-2020-0181
Pang, J., Liu, M., Ling, W., & Jin, T. (2021). Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment. Obesity Medicine, 22(January), 100312. https://doi.org/10.1016/j.obmed.2020.100312
Pautasso, M. (2019). The Structure and Conduct of a Narrative Literature Review. A Guide to the Scientific Career, 299–310. https://doi.org/10.1002/9781118907283.ch31
Pegah, A., Abbasi-Oshaghi, E., Khodadadi, I., Mirzaei, F., & Tayebinia, H. (2021). Probiotic and resveratrol normalize GLP-1 levels and oxidative stress in the intestine of diabetic rats. Metabolism Open, 10, 100093. https://doi.org/10.1016/j.metop.2021.100093
Penninger, J. M., Grant, M. B., & Sung, J. J. Y. (2021). The Role of Angiotensin Converting Enzyme 2 in Modulating Gut Microbiota, Intestinal Inflammation, and Coronavirus Infection. Gastroenterology, 160(1), 39–46. https://doi.org/10.1053/j.gastro.2020.07.067
Peterson, L. W., & Artis, D. (2014). Intestinal epithelial cells: Regulators of barrier function and immune homeostasis. Nature Reviews Immunology, 14(3), 141–153. https://doi.org/10.1038/nri3608
Praharaj, I., John, S. M., Bandyopadhyay, R., & Kang, G. (2015). Probiotics, antibiotics and the immune responses to vaccines. Philosophical Transactions of the Royal Society B: Biological Sciences, 370(1671). https://doi.org/10.1098/rstb.2014.0144
Ratajczak, W., Rył, A., Mizerski, A., Walczakiewicz, K., Sipak, O., & Laszczyńska, M. (2019). Immunomodulatory potential of gut microbiome-derived shortchain fatty acids (SCFAs). Acta Biochimica Polonica, 66(1), 1–12. https://doi.org/10.18388/abp.2018_2648
Robles-Vera, I., Toral, M., de la Visitación, N., Sánchez, M., Gómez-Guzmán, M., Muñoz, R., Algieri, F., Vezza, T., Jiménez, R., Gálvez, J., Romero, M., Redondo, J. M., & Duarte, J. (2020). Changes to the gut microbiota induced by losartan contributes to its antihypertensive effects. British Journal of Pharmacology, 177(9), 2006–2023. https://doi.org/10.1111/bph.14965
Rooks, M. G., & Garrett, W. S. (2016). Gut microbiota, metabolites and host immunity. Nature Reviews Immunology, 16(6), 341–352. https://doi.org/10.1038/nri.2016.42
Roy, K., Agarwal, S., Banerjee, R., Paul, M. K., & Purbey, P. K. (2021). COVID-19 and gut immunomodulation. World Journal of Gastroenterology, 27(46), 7925–7942. https://doi.org/10.3748/wjg.v27.i46.7925
Ruder, B., Atreya, R., & Becker, C. (2019). Tumour necrosis factor alpha in intestinal homeostasis and gut related diseases. International Journal of Molecular Sciences, 20(8). https://doi.org/10.3390/ijms20081887
Rutz, S., & Ouyang, W. (2016). Regulation of Interleukin-10 Expression (Issue Il, pp. 89–116). https://doi.org/10.1007/978-94-024-0921-5_5
Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N. (2021). Anti-inflammatory effects of GLP-1 in patients with COVID-19. Expert Review of Anti-Infective Therapy, 00(00), 1–9. https://doi.org/10.1080/14787210.2021.1964955
Scaldaferri, F., Ianiro, G., Privitera, G., Lopetuso, L. R., Vetrone, L. M., Petito, V., Pugliese, D., Neri, M., Cammarota, G., Ringel, Y., Costamagna, G., Gasbarrini, A., Boskoski, I., & Armuzzi, A. (2020). The thrilling journey of sars-cov-2 into the intestine: From pathogenesis to future clinical implications. Inflammatory Bowel Diseases, 26(9), 1306–1314. https://doi.org/10.1093/ibd/izaa181
Shetty, P., K, N. K., Patil, P., Bhandary, S. K., Haridas, V., N, S. K., & E, S. (2021). Is butyrate a natural alternative to dexamethasone in the management of CoVID-19? F1000Research, 10, 1–18. https://doi.org/10.12688/f1000research.51786.1https://doi.org/10.12688/f1000research.51786.1
Shokri-Afra, H., Alikhani, A., Moradipoodeh, B., Noorbakhsh, F., Fakheri, H., & Moradi-Sardareh, H. (2021). Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms. Scientific Reports, 11(1), 1–10. https://doi.org/10.1038/s41598-021-01231-4
Sonkar, C., Kashyap, D., Varshney, N., Baral, B., & Jha, H. C. (2020). Impact of Gastrointestinal Symptoms in COVID-19: a Mollecular Approach. SN Comprehensive Clinical Medicine, 1–12.
Sundararaman, A., Ray, M., Ravindra, P. V, & Halami, P. M. (2020). Role of probiotics to combat viral infections with emphasis on COVID-19. Applied Microbiology and Biotechnology, 104(19), 8089–8104. https://doi.org/10.1007/s00253-020-10832-4
Tao, W., Zhang, G., Wang, X., Guo, M., Zeng, W., Xu, Z., Cao, D., Pan, A., Wang, Y., Zhang, K., Ma, X., Chen, Z., Jin, T., Liu, L., Weng, J., & Zhu, S. (2020). Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18. Medicine in Microecology, 5(January). https://doi.org/10.1016/j.medmic.2020.100023
Trougakos, I. P., Stamatelopoulos, K., Terpos, E., Tsitsilonis, O. E., Aivalioti, E., Paraskevis, D., Kastritis, E., Pavlakis, G. N., & Dimopoulos, M. A. (2021). Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of Biomedical Science, 28(1), 9. https://doi.org/10.1186/s12929-020-00703-5
Udeh, R., Advani, S., Romualdo, L. G. de G., & Dolja-Gore, X. (2021). Calprotectin, an emerging biomarker of interest in covid-19: A systematic review and meta-analysis. Journal of Clinical Medicine, 10(4), 1–14. https://doi.org/10.3390/jcm10040775
Vecchié, A., Bonaventura, A., Toldo, S., Dagna, L., Dinarello, C. A., & Abbate, A. (2021). IL‐18 and infections: Is there a role for targeted therapies? Journal of Cellular Physiology, 236(3), 1638–1657. https://doi.org/10.1002/jcp.30008
Vignesh, R., Swathirajan, C. R., Tun, Z. H., Rameshkumar, M. R., Solomon, S. S., & Balakrishnan, P. (2021). Could Perturbation of Gut Microbiota Possibly Exacerbate the Severity of COVID-19 via Cytokine Storm? Frontiers in Immunology, 11(January), 1–7. https://doi.org/10.3389/fimmu.2020.607734
Villapol, S. (2020). Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. Translational Research, 226(May), 57–69. https://doi.org/10.1016/j.trsl.2020.08.004
Villena, J., Li, C., Vizoso-Pinto, M. G., Sacur, J., Ren, L., & Kitazawa, H. (2021). Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines. Microorganisms, 9(4), 683. https://doi.org/10.3390/microorganisms9040683
Vitetta, L., Saltzman, E. T., Thomsen, M., Nikov, T., & Hall, S. (2017). Adjuvant probiotics and the intestinal microbiome: Enhancing vaccines and immunotherapy outcomes. Vaccines, 5(4), 1–17. https://doi.org/10.3390/vaccines5040050
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020). Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. Journal of Virology, 94(7), 2019–2020. https://doi.org/10.1128/jvi.00127-20
Worlds Health Organization. (2021). WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/
Xiao, L., Sakagami, H., & Miwa, N. (2020). ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel? Viruses, 12(491), 2002–2003. https://doi.org/10.3390/v12050491
Xu, J., Ren, Z., Cao, K., Li, X., Yang, J., Luo, X., Zhu, L., Wang, X., Ding, L., Liang, J., Jin, D., Yuan, T., Li, L., & Xu, J. (2021). Boosting Vaccine-Elicited Respiratory Mucosal and Systemic COVID-19 Immunity in Mice With the Oral Lactobacillus plantarum. Frontiers in Nutrition, 8(December). https://doi.org/10.3389/fnut.2021.789242
Yeoh, Y. K., Zuo, T., Lui, G. C. Y., Zhang, F., Liu, Q., Li, A. Y. L., Chung, A. C. K., Cheung, C. P., Tso, E. Y. K., Fung, K. S. C., Chan, V., Ling, L., Joynt, G., Hui, D. S. C., Chow, K. M., Ng, S. S. S., Li, T. C. M., Ng, R. W. Y., Yip, T. C. F., … Ng, S. C. (2021). Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut, 70(4), 698–706. https://doi.org/10.1136/gutjnl-2020-323020
Yu, Z., Yang, Z., Wang, Y., Zhou, F., Li, S., Li, C., Li, L., Zhang, W., & Li, X. (2021). Recent advance of ACE2 and microbiota dysfunction in COVID-19 pathogenesis. Heliyon, 7(7), e07548. https://doi.org/10.1016/j.heliyon.2021.e07548
Zuo, T., Liu, Q., Zhang, F., & Lui, G. C.-Y. (2021). Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut, 70, 279–284.
Zuo, T., Zhang, F., Lui, G. C. Y., Yeoh, Y. K., Li, A. Y. L., Zhan, H., Wan, Y., Chung, A. C. K., Cheung, C. P., Chen, N., Lai, C. K. C., Chen, Z., Tso, E. Y. K., Fung, K. S. C., Chan, V., Ling, L., Joynt, G., Hui, D. S. C., Chan, F. K. L., … Ng, S. C. (2020a). Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology, 159(3), 944-955.e8. https://doi.org/10.1053/j.gastro.2020.05.048
Zuo, T., Zhang, F., Lui, G. C. Y., Yeoh, Y. K., Li, A. Y. L., Zhan, H., Wan, Y., Chung, A. C. K., Cheung, C. P., Chen, N., Lai, C. K. C., Chen, Z., Tso, E. Y. K., Fung, K. S. C., Chan, V., Ling, L., Joynt, G., Hui, D. S. C., Chan, F. K. L., … Ng, S. C. (2020b). Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology, 159(3), 944-955.e8. https://doi.org/10.1053/j.gastro.2020.05.048
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2022 Lívia Bruni de Souza; Vinicius Guzzoni; Tatiana Sousa Cunha
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores que publican en esta revista concuerdan con los siguientes términos:
1) Los autores mantienen los derechos de autor y conceden a la revista el derecho de primera publicación, con el trabajo simultáneamente licenciado bajo la Licencia Creative Commons Attribution que permite el compartir el trabajo con reconocimiento de la autoría y publicación inicial en esta revista.
2) Los autores tienen autorización para asumir contratos adicionales por separado, para distribución no exclusiva de la versión del trabajo publicada en esta revista (por ejemplo, publicar en repositorio institucional o como capítulo de libro), con reconocimiento de autoría y publicación inicial en esta revista.
3) Los autores tienen permiso y son estimulados a publicar y distribuir su trabajo en línea (por ejemplo, en repositorios institucionales o en su página personal) a cualquier punto antes o durante el proceso editorial, ya que esto puede generar cambios productivos, así como aumentar el impacto y la cita del trabajo publicado.
